Rigel Pharmaceuticals (STU:RI2A) Days Sales Outstanding : 89.54 (As of Mar. 2024)

View and export this data going back to 2013. Start your Free Trial

What is Rigel Pharmaceuticals Days Sales Outstanding?

Rigel Pharmaceuticals's average Accounts Receivable for the three months ended in Mar. 2024 was €26.7 Mil. Rigel Pharmaceuticals's Revenue for the three months ended in Mar. 2024 was €27.2 Mil. Hence, Rigel Pharmaceuticals's Days Sales Outstanding for the three months ended in Mar. 2024 was 89.54.

The historical rank and industry rank for Rigel Pharmaceuticals's Days Sales Outstanding or its related term are showing as below:

STU:RI2A' s Days Sales Outstanding Range Over the Past 10 Years
Min: 3.64 Med: 43.67 Max: 254.39
Current: 79.94

During the past 13 years, Rigel Pharmaceuticals's highest Days Sales Outstanding was 254.39. The lowest was 3.64. And the median was 43.67.

STU:RI2A's Days Sales Outstanding is ranked worse than
55.73% of 881 companies
in the Biotechnology industry
Industry Median: 72.67 vs STU:RI2A: 79.94

Rigel Pharmaceuticals's Days Sales Outstanding declined from Mar. 2023 (122.71) to Mar. 2024 (89.54).

Rigel Pharmaceuticals Days Sales Outstanding Historical Data

The historical data trend for Rigel Pharmaceuticals's Days Sales Outstanding can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Rigel Pharmaceuticals Days Sales Outstanding Chart

Rigel Pharmaceuticals Annual Data

Trend

Dec14

Dec15

Dec16

Dec17

Dec18

Dec19

Dec20

Dec21

Dec22

Dec23

Days Sales Outstanding

Get a 7-Day Free Trial

43.38

45.44

37.06

83.21

112.51

Rigel Pharmaceuticals Quarterly Data
	Jun19	Sep19	Dec19	Mar20	Jun20	Sep20	Dec20	Mar21	Jun21	Sep21	Dec21	Mar22	Jun22	Sep22	Dec22	Mar23	Jun23	Sep23	Dec23	Mar24
Days Sales Outstanding	Get a 7-Day Free Trial															122.71	85.76	71.44	69.61	89.54

Competitive Comparison of Rigel Pharmaceuticals's Days Sales Outstanding

For the Biotechnology subindustry, Rigel Pharmaceuticals's Days Sales Outstanding, along with its competitors' market caps and Days Sales Outstanding data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.

Rigel Pharmaceuticals's Days Sales Outstanding Distribution in the Biotechnology Industry

For the Biotechnology industry and Healthcare sector, Rigel Pharmaceuticals's Days Sales Outstanding distribution charts can be found below:

* The bar in red indicates where Rigel Pharmaceuticals's Days Sales Outstanding falls into.

Rigel Pharmaceuticals Days Sales Outstanding Calculation

Days Sales Outstanding measures the average number of days that a company takes to collect revenue after a sale has been made. It is a financial ratio that illustrates how well a company's Accounts Receivable are being managed.

Accounts Receivable can be measured by Days Sales Outstanding.

Rigel Pharmaceuticals's Days Sales Outstanding for the fiscal year that ended in Dec. 2023 is calculated as

	Days Sales Outstanding (A: Dec. 2023 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2022 )	+	Accounts Receivable (A: Dec. 2023 ))	/	count )	/	Revenue (A: Dec. 2023 )	*	Days in Period
=	( (38.062	+	28.014)	/	2 )	/	107.181	*	365
=	33.038					/	107.181	*	365
=	112.51

Rigel Pharmaceuticals's Days Sales Outstanding for the quarter that ended in Mar. 2024 is calculated as:

	Days Sales Outstanding (Q: Mar. 2024 )
=	Average Accounts Receivable					/	Revenue	*	Days in Period
=	( (Accounts Receivable (A: Dec. 2023 )	+	Accounts Receivable (A: Mar. 2024 ))	/	count )	/	Revenue (A: Mar. 2024 )	*	Days in Period
=	( (28.014	+	25.311)	/	2 )	/	27.171	*	365 / 4
=	26.6625					/	27.171	*	365 / 4
=	89.54

Rigel Pharmaceuticals (STU:RI2A) Days Sales Outstanding Explanation

For retailers, when we compare Days Sales Outstanding, it is important to compare the same period in the previous years.

Rigel Pharmaceuticals Days Sales Outstanding Related Terms

Thank you for viewing the detailed overview of Rigel Pharmaceuticals's Days Sales Outstanding provided by GuruFocus.com. Please click on the following links to see related term pages.

Rigel Pharmaceuticals (STU:RI2A) Business Description

Industry

GURUFOCUS.COM » STOCK LIST » Healthcare » Biotechnology » Rigel Pharmaceuticals Inc (STU:RI2A) » Definitions » Days Sales Outstanding

Comparable Companies

Traded in Other Exchanges

RIGL:USA

Address

611 Gateway Boulevard, Suite 900, South San Francisco, CA, USA, 94080

Website

https://www.rigel.com

Rigel Pharmaceuticals Inc develops small-molecule drugs for autoimmune, cancer-related, and viral diseases. The firm's lead drug is an oral rheumatoid arthritis drug candidate that has been licensed to AstraZeneca. Astra has taken overall responsibility to develop and market the drug and will pay Rigel royalties and milestone payments. Its pipeline product includes TAVALISSE (fostamatinib disodium hexahydrate) tablets, the only oral spleen tyrosine kinase (SYK) inhibitor, Fostamatinib, R289, R552, R835, DS-3032, THF-beta Inhibitors, and AZD0449- Inhaled JAK Inhibitor.

Rigel Pharmaceuticals (STU:RI2A) Headlines

No Headlines